Sage Group News

Kitov Pharmaceuticals Seeks a Commercial Partner for their Phase 3 Lead Product KIT-302, a Combinati

Kitov Pharmaceuticals, based in Israel, announces their lead product KIT-302. It combines Celecoxib (a COX-2 selective NSAID, the active ingredient in Pfizer’s Celebrex®) and Amlodipine (a neuronal calcium channel blocker), both successful products on the market. KIT-302 (Pending FDA approval will be named Concensi for the US market) demonstrated 2.5x better blood pressure reduction than the FDA requirement and also demonstrated consistent reduction in all measures of blood pressure. In addition, the Phase 3 study observed beneficial renal functions. A second Phase III study also met all its clinical endpoints and confirmed the findings of the first study. KIT-302 is a fixed dose combination